On Wednesday 6th November 2024, investors and market participants can expect the release of Coherus BioSciences (NASDAQ: CHRS) third quarter financial results. This crucial announcement will be made after market close.
The latest projections from financial analysts on Wall Street suggest that the enterprise is likely to reveal an estimated $0.12 loss per share for the quarter. Additionally, the company is expected to announce revenueS of $59.23 million for the period.
Financial analysts have shared their forecasts for the company's annual performance, indicating their belief that the company will achieve a total revenue of $261.52 million. Additionally, they predict that the earnings per share for the company will hit loss of $0.93 by the end of the fiscal year.
In the same quarter of the previous year, the company's financial statement revealed a per-share loss of $0.27. Additionally, the company's overall revenue for that particular period was an impressive $74.57 million.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.14 | +63.2% | 64.98 M | +10.7% |
| Q1 2024 | $-0.32 | +57.3% | 77.06 M | +137.6% |
| Q4 2023 | $-0.62 | -3.3% | 91.52 M | +101.8% |
| Q3 2023 | $-0.27 | +71.9% | 74.57 M | +64.2% |
| Q2 2023 | $-0.38 | +19.1% | 58.72 M | -2.4% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 6th November 2024 at 05:00 PM eastern time, in a conference call with public.
The previous trading day saw Coherus BioSciences (CHRS) shares trading between $0.71 and $0.76, besides a volume of 1.86 million shares. The stock closed Friday's regular trading session at $0.72, showing 4 percent drop.
